Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE)-Reference-Cited by-同舟云学术

Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE)

Published:2021-02-01 Issue:2 Volume:28 Page:103-123
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Yamashita Shizuya¹²,Arai Hidenori³,Bujo Hideaki⁴,Masuda Daisaku¹,Ohama Tohru¹⁵,Ishibashi Toshiyuki⁶,Yanagi Koji⁷,Doi Yasuji⁸,Nakagawa Satoshi⁹,Yamashiro Koichi⁹,Tanabe Kenichiro⁹,Kita Toru¹⁰,Matsuzaki Masunori¹¹,Saito Yasushi¹²,Fukushima Masanori⁹,Matsuzawa Yuji¹³,

Affiliation:

1. Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine

2. Department of Community Medicine, Osaka University Graduate School of Medicine

3. The National Center for Geriatrics and Gerontology

4. Department of Clinical Laboratory and Experimental Research Medicine, Toho University, Sakura Medical Center

5. Department of Dental Anesthesiology, Osaka University Graduate School of Dentistry

6. Ohara General Hospital

7. Kenporen Osaka Central Hospital

8. Saiseikai Senri Hospital

9. Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe

10. Kobe City College of Nursing

11. St. Hill Hospital

12. Chiba University Graduate School of Medicine

13. Sumitomo Hospital

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/28/2/28_55327/_pdf

Reference49 articles.

1. 1) Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A: Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet, 2015; 385: 1397-1405

2. 2) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators: Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015; 372: 2387-2397

3. 3) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 2017; 4; 376: 1713-1722

4. 4) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators: Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med, 2018; 379: 2097-2107

5. 5) Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D: Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest, 1986; 77: 641-644

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New perspectives on the high-density lipoprotein system and its role in the prevention and treatment of atherosclerotic cardiovascular disease;Current Opinion in Endocrinology, Diabetes & Obesity;2024-08-05

2. Probucol mitigates high-fat diet-induced cognitive and social impairments by regulating brain redox and insulin resistance;Frontiers in Neuroscience;2024-04-23

3. Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia;Genes;2024-02-26

4. The Process of Plaque Rupture: The Role of Vasa Vasorum and Medial Smooth Muscle Contraction Monitored by the Cardio-Ankle Vascular Index;Journal of Clinical Medicine;2023-11-30

5. The pathophysiology of excess plasma-free cholesterol;Current Opinion in Lipidology;2023-09-25